Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2

被引：0
|
作者：
Armstrong, April W. [1 ]
Liu, Yan [2 ]
Li, Nan [2 ]
Reich, Kristian [3 ]
Foley, Peter [4 ,5 ]
Li, Shu [6 ]
Fakharzadeh, Steven [2 ,6 ]
Papp, Kim A. [7 ,8 ]
Han, Chenglong [2 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA 90007 USA
[2] Janssen Global Serv LLC, Raritan, NJ USA
[3] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
[4] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[5] Skin Hlth Inst, Prob Med Res, Carlton, Vic, Australia
[6] Janssen Res & Dev LLC, Raritan, NJ USA
[7] K Papp Clin Res, Waterloo, ON, Canada
[8] Prob Med Res Inc, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27078
引用
收藏
页码：AB128 / AB128
页数：1
相关论文
共 50 条
  • [21] Sustained improvement in general health-related quality of life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 5-year data from clinical trial VOYAGE 2
    Reich, Kristian
    Gordon, Kenneth B.
    Foley, Peter
    Lomaga, Mark
    Han, Chenglong
    Miller, Megan
    You, Yin
    Radtke, Marc Alexander
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB174 - AB174
  • [22] Characterization of super responders to guselkumab treatment in moderate-to-severe psoriasis: results from the VOYAGE 1 and 2 clinical trials
    Reich, K.
    Gordon, K. B.
    Strober, B.
    Langley, R. G.
    Song, M.
    Shen, Y-K
    You, Y.
    Foley, P.
    Blauvelt, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 55 - 56
  • [23] LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2
    Gordon, Kenneth
    Armstrong, April
    Foley, Peter
    Wasfi, Yasmine
    Song, Michael
    Shen, Yaung-Kaung
    Li, Shu
    Munoz-Elias, Ernesto J.
    Randazzo, Bruce
    Reich, Kristian
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 23
  • [24] Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
    Reich, K.
    Papp, K. A.
    Armstrong, A. W.
    Wasfi, Y.
    Li, S.
    Shen, Y. K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1039 - 1049
  • [25] Estimated cost of reducing anxiety and depression in moderate to severe plaque psoriasis patients treated with guselkumab vs. adalimumab using results from the phase 3 VOYAGE 2 study
    Teeple, Amanda
    Han, Chenglong
    Muser, Erik
    Armstrong, April
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB206 - AB206
  • [26] Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
    Lebwohl, M.
    Papp, K.
    Han, C.
    Schenkel, B.
    Yeilding, N.
    Wang, Y.
    Krueger, G. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (01) : 137 - 146
  • [27] Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)
    Zhu, Xuejun
    Zheng, Min
    Song, Michael
    Shen, Yaung-Kaung
    Chan, Daphne
    Szapary, Philippe O.
    Wang, Baoxi
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (02) : 166 - 174
  • [28] Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2/3 trial
    Nakagawa, Hidemi
    Schenkel, Brad
    Kato, Mai
    Kato, Takeshi
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2012, 39 (09): : 761 - 769
  • [29] Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
    Blauvelt, Andrew
    Tsai, Tsen-Fang
    Langley, Richard G.
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Yang, Ya-Wen
    Papp, Kim A.
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 827 - 834
  • [30] Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
    Igarashi, Atsuyuki
    Kato, Takeshi
    Kato, Mai
    Song, Michael
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2012, 39 (03): : 242 - 252
12345